Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00172
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
Cot-APT<sub>EDB</sub>
|
|||||
| Peptide Type |
Linear
|
|||||
| Receptor Name |
Vesicle-associated membrane protein 8 (VAMP8)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
Cot-APTEDB-SN38 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Anti-tumor activity |
23.90%
|
|||
| Administration Time | 6 days | ||||
| Administration Dosage | Equivalent to 2 mg SN38/kg | ||||
| Description |
In situ HC[cot-APTEDB-SN38/Abcot] at an SN38/kg dose-equivalent of 2 mg effectively suppressed tumor growth and showed much greater antitumor activity (49.8% inhibition) than both cot-APTEDB-SN38 alone (23.9% inhibition) and CPT-11 (10.6% inhibition).
|
||||
| In Vivo Model | EDB-positive human glioblastoma-bearing mice. | ||||
| Half life period | 2.01 h | ||||
References